Navigation Links
Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both
Date:11/13/2013

WASHINGTON A molecule that helps cells stick together is significantly over-produced in two very different diseases rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial.

The study, published in Oncotarget, was led by investigators at Georgetown University Medical Center, and included collaborators from Harvard and Columbia Universities, Mayo Clinic and Queen's University in Belfast, Northern Ireland.

"Our findings suggest that cadherin-11 is important for cancer progression as well as rheumatoid arthritis for reasons we do not fully understand. Nevertheless, we are rapidly translating this discovery for use in the clinic," says the study's senior investigator, Stephen Byers, PhD, a professor and molecular oncologist at Georgetown Lombardi Comprehensive Cancer Center.

Byers and his Georgetown colleagues, Shahin Assefnia DVM, Siva Dakshanurthy PhD, and Jaime Guidry Auvil, PhD, have found that cadherin-11 is over-expressed in 15 percent of breast cancers, and in many glioblastomas. He believes the molecule also contributes to pancreatic cancer.

"What most of these cancers all have in common is cadherin-11 and a poor prognosis, with no effective therapies," Byers says. "Cadherin-11 expression is required for tumors to grow. If it is blocked, the cancers in cell line studies and in animals just stop growing which is really quite striking."

The Georgetown team has developed a small molecule agent to shut down cadherin-11 in cancer, and, by screening drugs now on the market, found that the well known arthritis drug Celebrex acts in a similar way. While it is unlikely that Celebrex could be used as a single agent against cancer because it would be too toxic at the level needed to impair cadherin-11, a Celebrex-related molecule works the same way, and may potentially be less toxic.

Co-author Michael Brenner, MD, at Harvard University, has designed an antibody that can shut down cadherin-11 in rheumatoid arthritis. The Oncotarget study demonstrated that Brenner's antibody worked in animal models of tumors that made cadherin-11.

It was chance that he and Brenner were working on the same molecule at the same time and came to know of each other's work. Coincidentally, co-author Lawrence Shapiro, PhD, at Columbia, was building a crystal structure of cadherin-11 and is now working with Byers and Brenner to show how the molecule binds to Celebrex and other small molecule drug cadherin-11 inhibitors.

This close collaboration led Byers, Brenner and Shapiro to apply for a grant last year from the National Cancer Institute's Provocative Questions project. They proposed answering the question related to the connection between drugs, such as anti-inflammatory agents, that can protect against cancer and other conditions.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Immune system molecule promotes tumor resistance to anti-angiogenic therapy
2. A new method for clicking molecules together
3. Metabolic molecule drives growth of aggressive brain cancer
4. Small molecule could have big impact on cancer
5. Molecule treats leukemia by preventing cancer cell repair, Jackson Laboratory scientists report
6. Moffitt Cancer Center researchers design small molecule to disrupt cancer-causing protein
7. Tiny RNA molecule may have role in polycystic ovary syndrome, insulin resistance
8. Signaling molecule may help stem cells focus on making bone despite age, disease
9. Novel small molecules used to visualize prostate cancer
10. Small molecules in the blood might gauge radiation effects after exposure
11. Molecules generated that can halt metastasis of colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss ... 2017 in San Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption ... hosted by Parks Associates, a market research and consulting firm specializing in emerging consumer ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients ... SPEED System™ Orthodontics, with or without a referral, from the multi-specialty Dr. Smile ... CA, who is skilled in providing patients with the custom, convenient and long-lasting ...
(Date:5/23/2017)... ... 23, 2017 , ... Patients in need of a pulpotomy in ... an appointment, with or without a referral. Dr. Cotey is a respected dental provider ... as a healthy alternative to a tooth extraction. , When a child has a ...
(Date:5/22/2017)... Mt. Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced ... can be administered for a variety of treatments. One or more sedation methods may ...
(Date:5/22/2017)... ... May 22, 2017 , ... Today, Our Urgent Care celebrates the grand ... public ribbon cutting ceremony. Since opening over a month ago, Our Urgent Care ... room. The new Our Urgent Care walk-in clinic is located at 3195 Phoenix ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology: